🔗 Share this article

As the US proceeds with unprecedented adjustments to its vaccine schedules, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccines during the pandemic and has zeroed in on possible fatalities following COVID-19 vaccination in her short time at the FDA.

Proposed Changes to Pediatric Immunization Program

Public health authorities had intended to unveil major revisions to the childhood vaccine schedule earlier this month, aligning the US with the Danish vaccine program, it is understood – a significant shift that would place the US out of alignment with many the world with no evidence for benefit. The announcement has been postponed until the next year.

In place of Vinay Prasad, Høeg is scheduled to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to head the division this calendar year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for halting certain childhood vaccine recommendations in the US to become more similar to Denmark, a country with universal health coverage and a population approximately the population of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – usually the purview of Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Qualifications

The appointee has no obvious experience in drug development, regulation or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “grasp laws and regulations and the research of medication creation”, said Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who led the center have had.”

This division has an immense portfolio at the FDA, she pointed out.

“The public just zeroes in on the novel medication approvals, but the generic program approves thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be supervised,” Woodcock explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant administrative aspect to the position, which oversees more than 5,000 employees. “It’s a huge leadership role, if you do it right,” Woodcock said.

Response and Controversial Programs

When asked about questions about Høeg’s credentials and whether this selection signifies more teamwork among regulatory chiefs on vaccines, a press secretary said that the “concerns stem from incorrect presumptions”.

“This background matches the functions of her job,” the official explained, citing the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial expedited review system, a contentious one-day drug-approval program that apparently troubled her former heads. “How are these therapies being picked for this voucher program? Who makes the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he said, “the FDA looks to be trending towards laxer oversight of most medications, with the exception of immunizations.”

Documented History on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, Howard observe. She published a research paper using non-validated crowd-sourced reports to determine the rate of heart inflammation following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming administration encompassed revising regulations for new vaccines and halting “unnecessary” immunizations, she said following the vote on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of barring teenage boys from receiving COVID-19 vaccines.

“She is an complete dogmatist who begins with her beliefs and reverse-engineers to retrofit the data in a very misleading, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow skeptics, {like|